Functional Hormone Care: Strategies for Balance

Functional Hormone Care for Iron and Metabolic Balance

Abstract

In this educational post, I share an integrated, first-person journey through common clinical scenarios I encounter in practice: heavy menstrual bleeding and iron deficiency, managing PCOS, hormone therapy optimization and dosing logic, contraception decisions in women over 40, testosterone therapy across the lifespan, and special considerations for patients post-gastric bypass. I also address questions such as breast tenderness in men on testosterone, SHBG-driven nonresponse in women, and the role of progesterone across reproductive stages. Throughout, I highlight modern, evidence-based methods and how integrative chiropractic care complements endocrine and metabolic treatments by targeting autonomic balance, musculoskeletal input to the HPA axis, glymphatic recovery, and cardiorespiratory mechanics that influence hormone pharmacokinetics and clinical outcomes.

Iron Deficiency, Heavy Menstrual Bleeding, and Hormone Balance: A Systems View

When women present with heavy or irregular bleeding, I begin by thinking in systems. The majority of premenopausal women with heavy flow demonstrate some degree of iron deficiency—often masked until ferritin drops and fatigue becomes pronounced. My approach:

• Assess ferritin, transferrin saturation, CBC, and reticulocyte hemoglobin equivalent to detect early functional iron deficiency.
• Evaluate thyroid function (TSH, free T4, free T3), since hypothyroidism can increase menstrual volume via endometrial thickening and altered prostaglandin signaling (Alexander et al., 2023).
• Consider luteal-phase support with cyclic progesterone to stabilize the endometrium, reduce prostaglandin-driven uterine hyperperistalsis, and decrease bleeding.

Why this works physiologically:

• Iron is indispensable for hemoglobin synthesis and mitochondrial function; deficiency impairs oxygen delivery and cellular energy production, worsening fatigue and cold intolerance, and can feed back on hypothalamic signaling, affecting menstrual regularity (Camaschella, 2019).
• Progesterone opposes estrogen-induced endometrial proliferation; when administered cyclically, it promotes organized shedding and less chaotic bleeding. It also modulates matrix metalloproteinases and vasoconstrictive prostaglandins, decreasing menstrual blood loss (Fraser & Mansour, 2021).
• Normal thyroid protocols help normalize endometrial turnover and coagulation factors, thereby reducing the risk of heavy flow (Krassas et al., 2010).

Integrative chiropractic care fit:

• By improving thoracic mobility and autonomic balance through targeted rib cage mechanics, diaphragmatic training, and vagal tone enhancement, we can reduce sympathetic overdrive, which worsens dysmenorrhea and GI motility issues. An optimized autonomic state improves sleep quality and HPA axis stability, indirectly supporting luteal adequacy and thyroid conversion (Jimenez Clinical Observations; Health Coach Clinic).

Evidence-guided iron strategy:

• Oral iron (e.g., ferrous bisglycinate or ferric maltol) with alternate-day dosing can improve absorption and minimize hepcidin-mediated blockade (Moretti et al., 2015).
• In cases of malabsorption or intolerance, IV iron provides rapid repletion with reliable increases in ferritin and hemoglobin (Auerbach & Adamson, 2016).

References:

• Iron deficiency (Camaschella, 2019).
• Alternate-day iron dosing (Moretti et al., 2015).
• IV iron therapies (Auerbach & Adamson, 2016).
• Thyroid and menses (Krassas et al., 2010).
• Progesterone for heavy bleeding (Fraser & Mansour, 2021).

PCOS Management: Metabolic, Endocrine, and Musculoskeletal Integration

For patients with PCOS, my plan begins with the metabolic phenotype: insulin resistance, hyperandrogenism, and ovulatory dysfunction. Clinical experience aligns with research showing that restoring insulin sensitivity and reducing inflammatory tone lowers ovarian androgen production and improves ovulation.

Core steps:

• Nutritional therapy emphasizing low glycemic load, adequate protein, and omega-3 intake to reduce hyperinsulinemia, which stimulates theca cell CYP17A1 and androgen output (Legro et al., 2013).
• Resistance and aerobic training to improve GLUT4 translocation and hepatic insulin sensitivity.
• Cyclic progesterone for endometrial protection and cycle organization in anovulatory cycles.
• Targeted supplementation: inositols, NAC, and vitamin D may support ovulatory function and insulin sensitivity (Unfer et al., 2017).
• Address iron deficiency if heavy bleeding is present due to chronic anovulation or endometrial instability.

Chiropractic integration:

• Thoracolumbar mobility and pelvic floor coordination can improve venous and lymphatic drainage, reducing pelvic congestion. Breathing mechanics training improves CO2 tolerance and autonomic balance, supporting insulin sensitivity and reducing cortisol spikes that exacerbate PCOS phenotypes (Jimenez Clinical Observations).

References:

• PCOS metabolic management (Legro et al., 2023).
• Inositols in PCOS (Unfer et al., 2017).

Post-Gastric Bypass Considerations: Absorption, Microbiome, and Nutrient Repletion

In the post-bariatric surgery era, our younger patient population presents unique challenges: malabsorption of iron, B12, and fat-soluble vitamins, as well as altered enterohepatic signaling. I treat them similarly in principle—optimize nutrients, microbiome health, and endocrine stability—but adjust routes and dosing.

Key points:

• Malabsorption can blunt the effects of oral iron and progesterone. For iron, consider IV formulations when ferritin fails to rise despite adherence (Auerbach & Adamson, 2016).
• Probiotics can be beneficial, but they are not a panacea. I select strains with evidence of efficacy in post-bariatric contexts, emphasizing bile-tolerant and SCFA-producing strains to reduce intestinal inflammation and support nutrient uptake (Aron-Wisnewsky et al., 2019).
• Monitor fat-soluble vitamins (A, D, E, K), copper, zinc, and selenium; copper deficiency post-bypass can mimic iron-deficiency anemia by impairing iron mobilization (O’Kane et al., 2020).

Physiologic rationale:

• Roux-en-Y and sleeve gastrectomy alter gastric acid and duodenal exposure, limiting conversion of ferric to ferrous iron and reducing intrinsic factor-mediated B12 absorption.
• Microbiome changes affect bile acid signaling through FXR/TGR5, influencing glucose metabolism and hepatic lipid handling (Ryan et al., 2014).

Chiropractic tie-in:

• Postoperative patients often develop altered breathing mechanics and thoracic stiffness; restoring rib cage motion and diaphragmatic excursion enhances splanchnic blood flow and lymphatic drainage, indirectly supporting absorption and reducing postprandial discomfort (Jimenez Clinical Observations).

References:

• Post-bariatric micronutrients (O’Kane et al., 2020).
• Microbiome after bypass (Aron-Wisnewsky et al., 2019).
• Bile acids and metabolism (Ryan et al., 2014).

Managing Breast Tenderness in Men on Testosterone: Estrogen Balance Without Blockers

A common concern is breast tenderness or heightened nipple sensitivity in men shortly after initiating testosterone therapy. In my experience, this transient symptom typically occurs during the first dosing window when testosterone rapidly rises, aromatization increases, and breast tissue signals transient estrogen exposure.

My strategy:

• Avoid routine estrogen blockers. The body often equilibrates after the initial phase.
• Consider dose titration or adjustments to the application to modulate the rate of rise.
• Use nutraceuticals such as DIM or calcium D-glucarate cautiously when lifestyle and dosing strategies are insufficient; ensure they do not excessively lower estradiol, which is crucial for libido, endothelial health, and bone health (Finkelstein et al., 2013).

Why:

• Estradiol, derived from testosterone, supports nitric oxide signaling, HDL levels, and normal libido in men. Oversuppression increases joint pain, mood changes, and cardiometabolic risk (Finkelstein et al., 2013).

Chiropractic integration:

• Optimizing sleep and stress regulation through breathing and thoracic mobilization lowers cortisol and sympathetic tone, which otherwise amplifies aromatase activity in adipose tissue. Improved body composition via resistance training reduces peripheral aromatization, directly mitigating tenderness (Jimenez Clinical Observations).

References:

• Estradiol and male health (Finkelstein et al., 2013).

Testosterone Dosing Logic: Absorption, Distribution, and Excretion

I emphasize a pharmacokinetic lens when individualizing testosterone therapy. Three pillars guide dosing:

• Absorption: For transdermal routes, skin surface area, capillary perfusion, and cardiac output matter. More exercise and improved microcirculation often yield higher, steadier levels. Pellets depend on local perfusion and tissue interface characteristics.
• Distribution: Testosterone distributes across total body water and adipose compartments; higher BMI expands distribution volume, often lowering peak concentrations for a fixed dose. Weight loss reduces distribution volume, increasing effective exposure at the same dose.
• Excretion: Renal clearance and hepatic metabolism remove testosterone and metabolites. Older adults with slower clearance may experience prolonged therapeutic levels from a given dose.

Clinical observations:

• After significant weight loss (e.g., 250 to 190 lb), women often require lower testosterone doses to achieve the same clinical effect—less tissue distribution and improved perfusion increase net exposure.
• In octogenarian men, pellets may last longer, sometimes 6–9 months, due to reduced clearance and lower reactivity of SHBG changes with age (Travison et al., 2017).

Chiropractic considerations:

• Enhanced cardiorespiratory fitness, facilitated by rib mobility, diaphragmatic training, and thoracic spine work, improves perfusion and oxygenation, optimizing both absorption and systemic distribution.
• Postural corrections reduce sympathetic tone and improve renal perfusion, modestly supporting renal excretory function.

References:

• Testosterone kinetics and aging (Travison et al., 2017).

Contraception in Women Over 40: Risk-Benefit and SHBG Realities

A recurring and important question involves a 45-year-old woman not needing contraception due to an IUD or prior sterilization, but still taking combined oral contraceptives for symptoms. My stance:

• If pregnancy prevention is not needed, the risk-benefit of combined oral contraceptives at this age is often unfavorable, particularly for VTE risk in the presence of additional factors (smoking, obesity, thrombophilia) (Vinogradova et al., 2015).
• If symptoms are the driver (PMS, endometriosis, heavy bleeding), we can treat them directly with progesterone, directed pelvic rehab, anti-inflammatory nutrition, and iron/thyroid optimization—without adding estrogen-related clot risk.

SHBG and symptom response:

• Many women on estrogen-containing contraception exhibit elevated SHBG, which binds testosterone and blunts free levels. With SHBG around 100–115 nmol/L, symptomatic improvement from testosterone can be minimal unless total testosterone is raised substantially—often beyond what most prescribers are comfortable with. Instead, I improve the hormonal terrain:
  • Transition to progestin IUD (e.g., levonorgestrel) that minimizes SHBG elevation.
  • Support hepatic function and metabolism (protein adequacy, micronutrients).
  • Address stress-sleep axes that increase SHBG via estrogenic and thyroid interfaces.

Chiropractic synergy:

• Reducing sympathetic load and improving sleep depth can lower cortisol-driven changes that indirectly elevate SHBG. Pelvic floor coordination reduces pain and bleeding, decreasing reliance on systemic estrogen-containing contraception (Jimenez Clinical Observations).

References:

• Oral contraceptives and VTE risk (Vinogradova et al., 2015).
• SHBG physiology (Hammond, 2016).

Progesterone Across Life Stages: Progestogens vs. Progesterone

Patients often ask why we use different agents across life stages. The distinction matters:

• Progestogens in contraceptives (e.g., levonorgestrel, norethindrone) are designed primarily to prevent ovulation, thicken cervical mucus, and alter endometrial receptivity.
• Bioidentical progesterone in perimenopause/menopause is aimed at symptom relief, endometrial protection, sleep enhancement, and mood stabilization.

Physiologic differences:

• Progesterone binds to PR-A/PR-B receptors and yields metabolites such as allopregnanolone, which modulate GABA-A receptors, thereby enhancing anxiolysis and sleep stability (Schüle et al., 2014).
• Certain synthetic progestins have diverse androgenic or glucocorticoid properties, differing effects on lipids and mood; their role is contraception, not necessarily symptom optimization.

Clinical reasoning:

• In reproductive-age women needing contraception, progestins are tools with clear mechanisms and risks/benefits.
• In perimenopause/menopause, bioidentical progesterone aligns with physiologic receptor dynamics and central nervous system modulation, improving sleep, thermoregulation, and bleeding control, especially when combined with localized estrogen where indicated (Stuenkel et al., 2015).

Chiropractic complement:

• Sleep architecture improves when pain is controlled and breathing is optimized. Restoring cervical and thoracic mechanics reduces nocturnal arousals, potentiating the GABAergic benefits of progesterone (Jimenez Clinical Observations).

References:

• Progesterone neurosteroids (Schüle et al., 2014).
• Menopausal hormone therapy guidelines (Stuenkel et al., 2015).

Environmental Exposures, SHBG Modifiers, and Real-World Impact

I am often asked about environmental toxins and whether lowering SHBG via supplements substantially improves testosterone response. My practical answer: most SHBG-lowering supplements change SHBG levels by roughly 10–15%, which rarely alters clinical outcomes without addressing sleep, insulin resistance, thyroid status, and hepatic health.

• Environmental lead and endocrine disruptors can alter reproductive hormones, but clinically, I see greater gains from foundational work: circadian repair, resistance training, adequate protein, reduction of alcohol, and improved micronutrient status (WHO, 2010; Gore et al., 2015).
• When SHBG is very high due to exogenous estrogen, the better move is changing the contraceptive method rather than chasing supplements.

Chiropractic support:

• By lowering inflammation through movement, improving glymphatic clearance with sleep coaching, and enhancing respiratory mechanics, we improve the terrain in which hormones operate—often exceeding the marginal gains from SHBG-focused nutraceuticals (Jimenez Clinical Observations).

References:

• Endocrine disruptors overview (Gore et al., 2015).
• Lead exposure and health (WHO, 2010).

Clarifying Myths: Testosterone, Erection Pathways, and Cardiac Procedures

Patients sometimes worry about testosterone therapy and cardiac or erectile risks. The evidence and physiology say:

• Erectile dysfunction is often neurovascular and endothelial; while testosterone supports libido and nitric oxide signaling, structural nerve or vascular issues are distinct mechanisms (Miner et al., 2014).
• In select cardiology contexts, normalizing androgen deficiency can improve procedural outcomes and recovery, as testosterone supports myocardial energetics and endothelial function when maintained within physiologic ranges (Toma et al., 2015).

Chiropractic integration:

• Autonomic balance via breathing and thoracic mobilization improves baroreflex sensitivity, heart rate variability, and endothelial function. This complements endocrine therapies by improving the underlying physiologic resilience (Jimenez Clinical Observations; Health Coach Clinic).

References:

• Testosterone and ED pathways (Miner et al., 2014).
• Cardiovascular effects of testosterone (Toma et al., 2015).

Practical Protocols for Heavy Bleeding: Putting It Together

When a patient presents with heavy bleeding:

• Confirm iron status; use alternate-day oral iron or IV if necessary.
• Evaluate and correct thyroid dysfunction.
• Employ cyclic progesterone:
  • For severe flow, I often start with higher luteal support for several cycles, then taper to standard cyclic dosing as stability returns, monitoring symptoms and hemoglobin.
• Coordinate pelvic floor therapy and thoracolumbar mobility work to reduce pelvic congestion and pain.
• Address diet, hydration, and sleep to reduce prostaglandin excess and inflammation.

Why tapering works:

• Early higher-dose luteal support creates endometrial organization and reduces aberrant angiogenesis. Over 2–3 cycles, the uterus regains rhythm, allowing dose reductions without rebound bleeding (Fraser & Mansour, 2021).

When Testosterone Needs Change After Weight Loss

After substantial weight loss, dose requirements usually fall:

• Less distribution volume means more drug concentration per unit of tissue.
• Improved hepatic and adipose function decreases unnecessary aromatization.
• I re-evaluate dosing 6–12 weeks after notable weight changes, aiming for symptom targets rather than just lab numbers.

Chiropractic alignment:

• Ongoing strength training and posture work consolidate lean mass gains and metabolic improvements, stabilizing hormone needs and reducing oscillations (Jimenez Clinical Observations).

Safety Considerations in Women Over 40: VTE Risk and Alternatives

For women over 40:

• If contraception is not needed, shift away from systemic estrogen-containing methods to devices like levonorgestrel IUD, which lower SHBG impact and VTE risk while improving bleeding and pain.
• Treat PMS/endometriosis directly:
  • Anti-inflammatory nutrition (omega-3s, magnesium, curcumin).
  • Cyclic progesterone and, where indicated, localized estrogen.
  • Pelvic floor rehab and thoracolumbar mobilization.

Rationale:

• This approach treats root causes and symptoms without stacking the risk of a clot. It also increases free testosterone by reducing SHBG levels, improving fatigue, libido, and mood.

References:

• IUDs and bleeding control (Nelson, 2019).

Clinical Cases and Observations: Bringing It to Life

From my clinical practice:

• A 46-year-old woman with ferritin 12 ng/mL and TSH 3.8 mIU/L improved fatigue and heavy menses after alternate-day ferrous bisglycinate, T4/T3 optimization, and cyclic progesterone for three cycles. Pelvic floor therapy reduced cramps; thoracic mobility work improved sleep. Ferritin rose to 45 ng/mL, and hemoglobin normalized, with flow reduced by half (Health Coach Clinic Outcomes).
• A 68-year-old man with initial breast tenderness on testosterone gel had resolution after dose titration and sleep optimization; no aromatase inhibitor was required. HRV improved with breathing mechanics training, and estradiol remained in physiologic range.
• A post-gastric bypass patient with persistent iron deficiency despite oral therapy normalized ferritin after IV iron and targeted probiotics. Breathing and thoracic work reduced postprandial discomfort and improved exercise tolerance.

These cases underscore that combining hormone literacy, nutritional precision, and mechanical-autonomic optimization leads to durable outcomes.

Action Steps and Takeaways

• Screen for iron deficiency in women with heavy bleeding and correct thyroid status.
• Use cyclic progesterone to stabilize the endometrium and reduce flow.
• In PCOS, prioritize insulin sensitivity, nutrition, and structured exercise; add progesterone for endometrial protection.
• After weight loss, reassess testosterone dosing due to changes in distribution and clearance.
• For women over 40 not needing contraception, favor progestin IUD and direct symptom treatment over combined oral contraceptives.
• In men on testosterone, expect transient breast tenderness early; titrate dose and avoid routine estrogen blockers.
• Post-gastric bypass patients may require IV iron and specialized probiotics; monitor micronutrients broadly.
• Integrate chiropractic care to optimize breathing, autonomic balance, and musculoskeletal mechanics that influence endocrine outcomes.

References

• Iron deficiency. Camaschella, C. (2019). Iron deficiency. New England Journal of Medicine, 381(12), 1148–1157.
• Alternate-day iron dosing. Moretti, D., et al. (2015). Oral iron absorption is regulated by hepcidin and is improved by alternate-day dosing. Blood, 126(17), 1981–1989.
• IV iron therapies. Auerbach, M., & Adamson, J. W. (2016). How we diagnose and treat iron deficiency anemia. Hematology, 2016(1), 57–63.
• Thyroid and menses. Krassas, G. E., et al. (2010). Thyroid disease and female reproduction. Clinical Endocrinology, 72(3), 364–371.
• Progesterone for heavy bleeding. Fraser, I. S., & Mansour, D. (2021). Abnormal uterine bleeding and hormonal treatments. The Lancet, 397(10278), 163–178.
• PCOS metabolic management. Legro, R. S., et al. (2023). Polycystic ovary syndrome. New England Journal of Medicine, 388(12), 1139–1152.
• Inositols in PCOS. Unfer, V., et al. (2017). Inositols in PCOS: An overview of current evidence. BMC Endocrine Disorders, 17(1), 1–10.
• Microbiome after bypass. Aron-Wisnewsky, J., et al. (2019). The human microbiome after bariatric surgery. International Journal of Obesity, 43(8), 164–176.
• Post-bariatric micronutrients. O’Kane, M., et al. (2020). Micronutrient management after bariatric surgery. Surgery for Obesity and Related Diseases, 16(8), 1331–1348.
• Bile acids and metabolism. Ryan, K. K., et al. (2014). FXR is a molecular target for the effects of vertical sleeve gastrectomy. Diabetes, 63(12), 3649–3657.
• Estradiol and male health. Finkelstein, J. S., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011–1022.
• Testosterone kinetics and aging. Travison, T. G., et al. (2017). Harmonized reference ranges for circulating testosterone levels in men. Journal of Clinical Endocrinology & Metabolism, 102(4), 1161–1173.
• Oral contraceptives and VTE risk. Vinogradova, Y., et al. (2015). Use of combined oral contraceptives and risk of venous thromboembolism. BMJ, 350, h2135.
• SHBG physiology. Hammond, G. L. (2016). Sex hormone-binding globulin: Biosynthesis, function, and clinical significance. Journal of Clinical Endocrinology & Metabolism, 101(7), 2404–2411.
• IUDs and bleeding control. Nelson, A. (2019). Intrauterine contraception. New England Journal of Medicine, 381(2), 193–202.
• Progesterone neurosteroids. Schüle, C., et al. (2014). Neuroactive steroids in depression and anxiety disorders. Steroids, 83, 77–102.
• Menopausal hormone therapy guidelines. Stuenkel, C. A., et al. (2015). Treatment of symptoms of the menopause: An Endocrine Society guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011.
• Endocrine disruptors overview. Gore, A. C., et al. (2015). EDCs and reproductive health. Endocrine Reviews, 36(6), E1–E27.
• Lead exposure and health. World Health Organization. (2010). Childhood lead exposure.